In this study, we demonstrated that RSK is overexpressed and hyperactivated in AML, and that high levels confer an adverse prognosis, suggesting RSK inhibition as a potential therapeutic target in AML. This evidence concerns the gene RPS6KA3 and acute myeloid leukemia.